2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

1463 EP300 loss-of-function drives mitochondrial dysfunction, leading to a targetable BCL-XL vulnerability in North American adult T-cell leukemia/lymphoma patients

Mrunmai Niljikar, MS, Julia Gagliardi2, B. Hilda Ye, PhD3, Christina Glytsou, PhD4, Advaitha Madireddy, PhD5
1 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
2 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
3 Albert Einstein College of Medicine, Bronx, New York, United States
4 Ernest Mario School of Pharmacy, Piscataway, New Jersey, United States
5 Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive CD4+ T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection, with a median survival of less than one year. North American ATLL (NA-ATLL), which disproportionately affects individuals of Caribbean and African descent, presents a distinct molecular landscape and worse clinical outcomes compared to Japanese ATLL. Recent genomic studies have identified histone acetyltransferase and transcriptional coactivator EP300 as one of the most recurrently mutated genes in NA-ATLL, with loss-of-function mutations present in approximately 15–25% of cases. Despite the high prevalence and prognostic significance of EP300 mutations, the functional consequences of p300 loss on cellular metabolism and survival in ATLL remain entirely unexplored.

Methods: We used a unique biorepository of patient-derived NA-ATLL cell line models comprising EP300-wild-type (NA1, NA4) and EP300-mutant (NA2, NA3) specimens, together with acute, orthogonal degradation of EP300 in wild-type cells using the EP300-selective PROTAC, JQAD1. Assays included quantitative proteomics, transcriptomics, OXPHOS immunoblotting, mitochondrial membrane potential (TMRM) and ROS flow cytometry, Seahorse extracellular flux assay, transmission electron microscopy (TEM), and cell viability assays with a selective BCL-XL inhibitor +/- BCL2 inhibitor Venetoclax (ABT-199).

Results: Total proteomics identified downregulation of the electron transport chain (ETC) in EP300-mutant cells, spanning complex I (NDUFS1/S6/S7, NDUFV1, NDUFA10/A12), II (SDHA, SDHB), III (UQCRH), IV (COX5A/5B, COX6A1/6B1, COX7A2/7C, MT-CO2) and V (ATP5IF1). Pharmacologic EP300 degradation in wild-type cells phenocopied this signature, and immunoblotting confirmed loss of complex I (NDUFB8), II (SDHB), and IV (MT-CO2) in both EP300-mutant and JQAD1-treated cells. Functionally, EP300-mutant cells showed loss of mitochondrial membrane potential, elevated ROS, and markedly reduced maximal and spare respiratory capacity by Seahorse analysis. JQAD1 recapitulated each of these defects in wild-type cells. Transmission electron microscopy demonstrated abnormal cristae in the majority of mitochondria from EP300-mutant cells (~93% NA2, ~95% NA3) as compared to EP300 wild-type cells (~48% NA1, ~55% NA4; p<0.0001), and EP300 degradation increased abnormal cristae in wild-type cells to 85% (p<0.001), indistinguishable from EP300-mutant cells. Proteomics further revealed remodeling of the apoptotic machinery in EP300-mutant cells, including altered BCL2-family of proteins (BCL2, BCL2L1/BCL-XL, BCL2L2, BCL2L11/BIM). This translated into a selective vulnerability, where EP300-mutant ATLL cells were exquisitely sensitive to BCL-xL inhibition (IC50 approximately 3 nM; >90% killing at 100 nM) whereas EP300-wildtype cells were largely resistant (IC50 >100 nM; p<0.0001). Addition of venetoclax further lowered the IC50 in EP300-mutant cells and partially sensitized EP300-wildtype cells.

Conclusions: EP300 loss of function is a direct driver of ETC deficiency, cristae disorganization, depolarization, and oxidative stress in NA-ATLL, established by concordant genetic and pharmacologic approaches. This mitochondrial reprogramming is accompanied by apoptotic priming that renders EP300-mutant cells selectively dependent on BCL-XL, a dependency deepened by venetoclax. These data define EP300 mutation as a biomarker of BH3-mimetic sensitivity and nominate BCL-XL inhibition, alone or with venetoclax, as a rational therapeutic strategy for a disease with no effective treatment options.
Mrunmai Niljikar, MS: No relevant conflicts of interest to declare.